Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 10
One Retatrutide Patient Is Not a Trial
One person reportedly received retatrutide through expanded access. Here is what that means, and why it is not approval or trial evidence.
Retatrutide special access criteria
Lilly will review more retatrutide access requests, but FDA criteria, trial eligibility, company agreement, and ethics review still apply.
Tirzepatide and visceral fat in Japan
A SURMOUNT J analysis links tirzepatide related weight loss with lower visceral fat and changing metabolic markers in Japan.
How GLP-1 Drugs Change What You Eat
A new narrative review details how semaglutide and tirzepatide reshape appetite, food choice, and nutrient intake, not just meal size.
The Real Risks of Grey-Market Peptides
Unapproved injectable peptides like TB-500, sold online with no prescription, carry contamination, dosing, and safety risks the FDA is still reviewing.
MASLD Screening Without a Liver Biopsy
A new review explains how FIB-4 screens for MASLD and MASH in primary care, now that semaglutide and resmetirom can treat confirmed cases.
What Patients Want in an Obesity Drug
A US survey of 800 adults finds route of administration and weight-loss efficacy outweigh simpler dosing rules when picking an obesity medication.
Ozempic Face: What the Research Says
Researchers reviewed 23 resources on GLP-1 drugs and facial volume loss. A peer response says the evidence for a distinct semaglutide effect is weak.
Semaglutide and Bipolar Disorder: The Data
A Swedish national cohort links semaglutide, not other GLP-1 drugs, to fewer bipolar hospitalizations. Here is what the data shows and does not yet show.
Why semaglutide alone beat the CRV431 combo
In a mouse model of advanced liver disease, semaglutide alone reduced tumor burden more than adding the investigational compound CRV431.
Tirzepatide, Dulaglutide: Patient Voices
Exit interviews from the SURPASS-CVOT trial capture what patients on tirzepatide and dulaglutide said helped, and what did not.
Tesamorelin under 1mg: what the data says
Egrifta's labeled tesamorelin dose is 1.28 mg daily, and no trial has published data below 1 mg or tested it against sermorelin.